Aardvark Therapeutics, Inc. Common Stock AARD Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$21.59M-132% | -$17.6M-100% | -$16.32M-290% | -$14.37M-164% | -$9.31M-327% | ||
| $11K+120% | $10K+25.0% | $10K+25.0% | $11K+650% | $5K+150% | ||
| $2M+760% | $1.58M+814% | $1.5M+934% | $634K+1,074% | $233K+248% | ||
| —— | $0— | $0— | $0-100% | $0-100% | ||
| $2.42M+274% | —— | —— | $2.58M+306% | $648K+246% | ||
| -$1.26M-189% | $2.17M— | $1.03M+255% | $1.81M+194% | $1.41M+191% | ||
| $333K-92.4% | $369K+29.0% | $1.31M— | $0-100% | $4.36M+1,214% | ||
| -$13K+13.3% | -$19K+58.7% | $36K+140% | -$7K-123% | -$15K+86.4% | ||
| -$105K-98.1% | -$104K-16.9% | -$100K-81.8% | -$81K-200% | -$53K-96.3% | ||
| -$18.87M-65.7% | -$16.81M-118% | -$16.13M-308% | -$9.84M-134% | -$11.39M-420% | ||
| —— | $0-100% | $4K-20.0% | $91K-2.2% | $0-100% | ||
| $0-100% | $4.95M-58.4% | —— | —— | $124.65M— | ||
| $34.25M+185% | $29.25M— | $29.25M— | $9.5M— | $12.03M— | ||
| $34.25M+130% | —— | —— | —— | -$112.62M-2,252,380% | ||
| $4K-96.4% | —— | $171K+1.2% | $6K— | $110K— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $4K-100.0% | $274K— | $171K+167% | $0-100% | $88.88M— | ||
| $15.39M+144% | —— | —— | -$506K-101% | -$35.14M-1,501% | ||
| $118K+45.7% | $233K+143% | $372K— | $620K— | $81K— | ||
| -$105K-98.1% | -$104K-16.9% | -$100K-81.8% | -$81K-200% | -$53K-96.3% | ||
| $333K-92.4% | $369K+29.0% | $1.31M— | $0-100% | $4.36M+1,214% | ||
| $86K-19.6% | $84K-20.8% | $83K+5.1% | $106K+324% | $107K+328% | ||
| $0-100% | $4.95M-58.4% | —— | —— | $124.65M— | ||
| $34.25M+185% | $29.25M— | $29.25M— | $9.5M— | $12.03M— | ||
| $0-100% | —— | —— | $77K— | $2.31M— | ||
| $0-100% | —— | —— | —— | $91.08M— | ||
| -$105K-98.1% | -$104K-16.9% | -$100K-81.8% | -$81K-200% | -$53K-96.3% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$13K+13.3% | -$19K+58.7% | $36K+140% | -$7K-123% | -$15K+86.4% | ||
| $0-100% | —— | —— | —— | $126.76M— | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| —— | $6.5K+225% | $6.5K+225% | $6.5K+225% | $6.5K+225% | ||
| —— | -$16.81M-117% | -$16.13M-307% | -$9.94M-131% | -$11.39M-419% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aardvark Therapeutics, Inc. Common Stock generate?
- Aardvark Therapeutics, Inc. Common Stock (AARD) generated -$61.7M in operating cash flow over the trailing twelve months.
- Where does Aardvark Therapeutics, Inc. Common Stock's cash flow data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.